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To the editor: 
  
Primary mediastinal B cell lymphoma (PMBCL) is a rather infrequent aggressive 
lymphoma, putatively arising from a transformed thymic B cell. It accounts for less than 5% 
of all non-Hodgkin’s lymphomas, and typically affects adolescents and young women in 
their third or fourth decade of life.1 PMBCL should be often regarded as a hematological 
emergency and promptly treated: the initial treatment decision is crucial for the 
management of this disease. 
PMBCL has been recognized as a subtype of diffuse large B cell lymphoma (DLBCL) 
since the 1994, and it has been regarded as a specific clinical and biological entity since 
2001 by the World Health Organization classification. Apart from its peculiar clinical 
presentation and pathological features, PMBCL also displays an unique molecular 
fingerprint, which clearly distinguishes it from the other DLBCLs and partly overlaps with 
the molecular profile of nodular sclerosis Hodgkin’s disease (HD, at least a third of its 
genes, abnormalities on chromosome 9p and, although weaker,  the CD30 expression).2-5 
Relapse tends to occur early during the post-treatment follow-up, mostly within the first 
18 months, involving approximately 15-20% of patients (half of the cases are refractory). 
Disease at relapse generally behaves aggressively: it may remain confined to the 
mediastinum or spread to subdiaphragmatic organs. Outcomes for patients with relapsed 
or refractory PMBCL are generally poorer than those observed for a matched population of 
DLBCL patients. Overall survival (OS) at 2 years after the first relapse is just half of the 
one seen for DLBCL, even when appropriate salvage treatments (e.g. platinum-based or 
other intensive regimens) and autologous stem cell transplantation (ASCT) are timely 
applied.6,7 To note that adding rituximab to first line treatment improves outcomes.8,9 
High-dose treatment and ASCT, however, can influence prognosis, mostly in patients 
who were in partial response (PR) before ASCT: a recent retrospective study from Japan 
documented a significantly higher OS for transplanted versus not-transplanted patients 
(67% and 31% respectively),10 and a chance of cure can be observed in 40% - 80% of 
patients with disease that favorably responds to salvage treatment, according to different 
series.11-14 However, about 15% of patients with refractory disease remain free of 
progression after ASCT.6,11 
Brentuximab vedotin (BV) is a potent anti-CD30 antibody drug conjugate that has 
been approved in relapsed/refractory HD after ASCT and anaplastic large-cell lymphoma 
(ALCL). Beyond these consolidated indications, BV has been and is being tested in 
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different settings and hematologic diseases with promising results. The CD30 antigen is 
present in the majority of cases of PMBCL (80%), although it is expressed 
heterogeneously.1,5 A recently published phase II trial of BV in patients with 
relapsed/refractory DLBCL included also 6 patients with PMBCL: a 17% overall response 
rate (ORR) was observed, and half of patients maintained disease stability. Responses did 
not correlate with the quantitative CD30 expression on tumor cells.15  
Based on these premises, a single-arm, open-label, multicenter, phase II clinical 
trial evaluating the efficacy and safety of BV as a single agent in patients with 
relapsed/refractory histologically-confirmed CD30-positive PMLBCL was conceived and 
conducted by the Italian Lymphoma Foundation. The study was approved by the 
institutional review board and the Ethical Committees and has been performed in 
accordance with the ethical standards as laid down in the Declaration of Helsinki (EudraCT 
number: 2012-000735-27, NCT02423291). All the patients provided written informed 
consent.  
BV was administered at the dose of 1.8 mg/kg as a single IV infusion on day 1 of 
each 21-day cycle. Patients who achieved stable disease (SD) or better as assessed by 
investigator should receive a minimum of 8, but no more than 16 cycles of study treatment. 
Measures of anti-cancer activity were assessed using the revised response criteria for 
malignant lymphoma.16 Dedicated computed tomography scans were scheduled at 
baseline and at Cycles 2, 4, 7, 10, 13, and 16 and positron emission tomography scans 
were done at baseline and at Cycles 4 and 7. Severity of adverse events (AEs) was 
graded per National Cancer Institute Common Terminology Criteria for Adverse Events 
v4.0. Primary endpoint was ORR; key secondary endpoints included complete remission 
(CR) rate, duration of response, progression-free survival, OS, and safety.  
The safety population consists of all patients who received 1 dose of study drug 
and the efficacy population comprises all patients who had 1 post-baseline tumor 
assessment. 
From October 2013 to October 2015, 15 patients were enrolled in five Italian 
centers. Median age was 29.3 years (range, 19-73), 10/15 (67%) were females, and 5/15 
(34%) presented B symptoms. Median number of prior treatments was 3 (range, 1-4), 12 
(80%)  / patients were refractory to the last therapy before BV. All patients previously 
received rituximab, 8 (53.3%) ASCT, and 9 (60%) radiation (Table 1).  
The ORR was 13.3% (2/15): two patients achieved PR, 1 patient had SD and the 
remaining 12 patients had progression of disease (PD). One patient obtained PR after four 
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cycles, then he relapsed at 7th cycle, and one patient obtained PR after seven cycles, 
underwent allogeneic transplant and relapsed three months later. The other 12 patients 
showed PD between the 2th and the 7th cycle. The patient with SD stopped the treatment 
after cycle 2 for a serious AE not related to BV, namely a grade 5 intestinal perforation, 
and subsequently died. 
Six patients (40%) experienced BV-related AEs, mostly grade 1-2: 1 peripheral 
neuropathy, 1 atrial fibrillation (grade 2, rapidly resolved), 2 ALT and GGT increase and 2 
anemia. One patient experienced BV-related grade 3 fatigue. Hematologic toxicities not 
BV-related were all grade 1-2, except for two transient grade 4 granulocytopenia. No 
pulmonary, renal, vascular, metabolic, or infective toxicities were recorded. Time-to-point 
events were not estimated due to limited sample size and short duration of observations. 
Twenty patients were originally planned but the study coordinator decided to stop 
the trial beforehand due to drug inefficacy. On the basis of these results BV has to be 
considered no active in the setting of relapsed/refractory PMLBCL: only 13.3% (n=2) of the 
patients obtained a PR without any evidence of CR and the duration of these responses 
was less than 3-4 months (despite a patient underwent subsequently consolidation with 
allotransplant). Only another experience with BV in relapsed/refractory PMLBCL was 
reported: the ORR was 17% (only one CR out of 6 patients).15 This low response rate in 
PMLBCL was a real unexpected finding because this histologic subtype is typically 
characterized by high CD30 expression. 
In conclusion, BV had a manageable safety profile but a real low antitumor activity 
in patients with relapsed/refractory PMBCL, representing an unusual situation among the 
CD30+ lymphomas such as HD, ALCL, cutaneous T-cell lymphoma and DLBCL for which 
the ORR after BV ranges between 30% and 80%. The issue regarding the relation 
between BV efficacy and the level of CD30 expression is worth additional investigation in 
order to elucidate its mechanism and identify eligible patients for BV therapy more 
effectively and multi-disciplinary efforts are necessary. On the other hand, if BV activity is 
independent of CD30 expression, an alternative mechanism of activity, such as antigen 
presentation, may offer a rationale for continued exploration in combination.  
As not originally planned, we are now conducting a retrospective post-hoc analysis 
on CD30 expression in the 15 enrolled patients with the aim to compare their CD30 
expression pattern with the one of a matched HL cohort of patients who achieved a 
response after BV therapy at our Institute. Since per study protocol results of CD30 
expression from the most recent post-diagnostic biopsy of relapsed/refractory disease had 
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to be obtained from pathology reports, it is not said that the available biopsy was the one 
performed just before BV therapy and a bias in this analysis could occur. A prospective 
study could be also needful to test the possible biologic resistance despite target 
availability.  
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Table 1. Patient demographics and characteristics at baseline 
 
 n = 15 
Median age at therapy, years (range) 29.3 (19.5-73.4) 
Male, n (%) 5 (33.3) 
Stage, n (%) 
- I/II  
- III 
- IV 
 
7 (46.7) 
0 (0) 
8 (53.3) 
IPI, n (%) 
- 0 
- 1 
- 2 
- 3 
 
1 (6.7) 
5 (33.3) 
5 (33.3) 
4 (26.7) 
Systemic symptoms, n (%) 5 (33.3) 
Median LDH, U/l (range) 569 (250-3196) 
Refractory to most recent therapy, n (%) 32 (74.4) 
Median number of previous therapies (range) 3 (1-4) 
Prior autologous stem cell transplant, n (%) 8 (53.3) 
Prior radiotherapy, n (%) 9 (60.0) 
IPI, International Prognostic Index. LDH, lactic acid dehydrogenase. 
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